Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2700 participants
OBSERVATIONAL
2017-04-09
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
NCT03197155
Side Effects After Direct-acting Antiviral Treatment
NCT03346941
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
NCT00445315
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
NCT06010524
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
NCT03501550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Direct Acting Agents
No Intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viral Hepatitis Society
OTHER
Fehmi Tabak
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fehmi Tabak
Prof. Fehmi Tabak
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fehmi Tabak, Prof
Role: PRINCIPAL_INVESTIGATOR
Viral Hepatitis Society
Tansu Yamazhan, Prof
Role: STUDY_DIRECTOR
Viral Hepatitis Society
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cerrahpasa Medical Faculty
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dirican E, Bal T, Onlen Y, Sarigul F, User U, Sari ND, Kurtaran B, Senates E, Gunduz A, Zerdali E, Karsen H, Batirel A, Karaali R, Guner HR, Yamazhan T, Kose S, Erben N, Ince NK, Koksal I, Oztoprak N, Yoruk G, Komur S, Kaya SY, Bozkurt I, Gunal O, Yildiz IE, Inan D, Barut S, Namiduru M, Tosun S, Turker K, Sener A, Hizel K, Baykam N, Duygu F, Bodur H, Can G, Gul HC, Tartar AS, Celebi G, Sunnetcioglu M, Karabay O, Kumbasar Karaosmanoglu H, Sirmatel F, Tabak OF. Assisting the Diagnosis of Cirrhosis in Chronic Hepatitis C Patients Based on Machine Learning Algorithms: A Novel Non-Invasive Approach. J Clin Lab Anal. 2025 Jun;39(12):e70054. doi: 10.1002/jcla.70054. Epub 2025 May 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEPCTURKEY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.